Abstract
Alefacept (Amevive®, Astellas) is a recombinant dimeric fusion protein combining the Fc fragment of human IgG1 with the CD2-binding portion of the human leukocyte antigen-3 (LFA-3).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alefacept (Amevive®) Prescribing Information Astella, May 2012
Bhutani T, Kamangar F, Zitelli K et al (2012) Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study. J Dermatol Treat doi:10.3109/09546634.2012.672712
Lui H, Gulliver W, Hong TJ et al (2012) A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response. J Drugs Dermatol 11:929–937
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Alefacept. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_43
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_43
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)